NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Samson DJ, Ratko TA, Rothenberg BM, et al. Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May. (Comparative Effectiveness Reviews, No. 20.)

Cover of Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer

Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet].

Show details

Appendix BExcluded Studies

Full Review Codes
Key Question Codes
NRQnot relevant question (note if ANM, NDE, NRD, NRO, NRT)
Q#?unclear if relevant to any key question
Study Design Codes
ADBadministrative database
ANManimal study
CEAcost/cost-effectiveness analysis
CCScase-control study
COHcohort study
COMcommentary
CRcase report (n≤5)
CScase series
D?design unclear/possibly relevant
DACdiagnostic accuracy study
DPCdose planning study, comparative
DPNdose planning study, noncomparative
EDTeditorial
GUIguideline
INVin vitro
LTRletter
MAmeta-analysis
NABno abstract
NDEnot relevant design
NPDno primary data
NRAnarrative review article
PIphase I trial
PIIphase II trial
PHYphysics study
PHNphantom study
POSpatient positioning study
PRGprognostic study
PROprospective single-arm study
QEXquasi-experimental study (nonrandomized comparative)
RADradiology/imaging study
RCTrandomized controlled trial
REGregistry
RETretrospective study
SRsystematic review
STGdisease staging study
XSLcross-sectional study
Sample Size Code (single-arm only)
FEWn < 10
N1010 ≤ n < 25
N2525 ≤ n < 50
N5050 ≤ n < 100
N100n ≥ 100
N?n unclear
Disease Codes
CNTcentral nervous system tumor (including spine)
CRNcranial nerve tumors
CUTcutaneous tumors (melanoma, etc.)
DS?disease unclear
EARear tumors
ESTesophageal or precursors
ETHethmoid sinus
EYEeye tumors
HEMhematologic tumor(including lymphoma
HNUhead & neck unspecified
HYPhypopharyngeal
LARlaryngeal
MAXmaxillary sinus
MIXmixed head and neck
NRDnot relevant disease
NPHnasopharyngeal
OCLoral cavity/lip
OHNother head and neck tumor
OPHoropharyngeal
OSTother non-head and neck solid tumor
PARparaganglioma
PHRpharyngeal
PNSparanasal sinus/nasal cavity
PTHparathyroid
SALsalivary gland, including parotid
SBskull base tumors
SINsinus unspecified
THYthyroid
TRtracheal tumors
UNPunknown/occult primary
Intervention Codes
3DC3D conformal RT
2.5D2 ½ D RT
2DR2D conventional RT
ACCaccelerated fractionation
BSTboost dose
BRAbrachytherapy
CHTchemotherapy only
CRTchemoradiotherapy
CTPcytoprotective agent
DFRdefinitive RT
HYFhyperfractionation
IMRIMRT
IMMwith immobilization
METmetastatic
NBTneutron beam therapy
NRTnot relevant treatment
PALpalliative
PBTproton beam therapy
PCRpostoperative CRT
PSTpostoperative (adjuvant)
PREpreoperative (neoadjuvant)
RECrecurrent (reirradiation)
RSEradiosensitizing agent
SRSstereotactic radiosurgery
SRTstereotactic radiotherapy
SURsurgery only
T?treatment unclear
UCFunspecified conformal RT
URTunspecified radiotherapy
  1. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol. 2007;5(2):79–81. [No author] Rec #: 1840. Reprint: EXC NPD. [PubMed: 17344795]
  2. AstraZeneca. Formulary. 1999;34(10 SUPPL):13–18. [No author] Rec #: 27340. Reprint: EXC NRD.
  3. Aarstad AK, Aarstad HJ, Bru E, et al. Psychological coping style versus disease extent, tumour treatment and quality of life in successfully treated head and neck squamous cell carcinoma patients. Clin Otolaryngol. 2005;30(6):530–538. Rec #: 3920. Reprint: EXC URT, MIXED. [PubMed: 16402979]
  4. Abayomi OK. Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta Oncol. 2002;41(4):346–351. Rec #: 8970. Reprint: EXC NRA. [PubMed: 12234025]
  5. Al-Nawas B, Al-Nawas K, Kunkel M, et al. Quantifying radioxerostomia: salivary flow rate, examiner's score, and quality of life questionnaire. Strahlenther Onkol. 2006;182(6):336–341. Rec #: 3330. Reprint: EXC T? URT. [PubMed: 16703289]
  6. Allen AM, Tishler RB. Commentary: IMRT for head and neck cancer: many chapters left to write. Oncologist. 2007;12(5):565–568. Rec #: 1460. Reprint: EXC COM. [PubMed: 17522244]
  7. Amosson CM, Teh BS, Mai WY, et al. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy. Semin Oncol. 2002;29(6 Suppl 19):71–79. Rec #: 8600. Reprint: EXC DPN. [PubMed: 12577249]
  8. Anand AK, Jain J, Negi PS, et al. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 2006;18(6):497–504. Rec #: 2880. Reprint: EXC N10. [PubMed: 16909975]
  9. Ang KK. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol. 1998;8(4):230–236. Rec #: 36730. Reprint: EXC MA. [PubMed: 9873100]
  10. Ask A, Bjork-Eriksson T, Zackrisson B, et al. The potential of proton beam radiation therapy in head and neck cancer. Acta Oncol. 2005;44(8):876–880. Rec #: 4110. Reprint: EXC NRA. [PubMed: 16332595]
  11. Astreinidou E, Dehnad H, Terhaard CH, et al. Level II lymph nodes and radiation-induced xerostomia. Int J Radiat Oncol Biol Phys. 2004;58(1):124–131. Rec #: 7560. Reprint: EXC N10. [PubMed: 14697429]
  12. Back M, Oliver L, Bromley R, et al. Multicentre quality assurance of intensity-modulated radiotherapy planning: beware the benchmarker. J Med Imaging Radiat Oncol. 2008;52(2):197. Rec #: 28870. Reprint: EXC NRQ. [PubMed: 18373816]
  13. Baker SR, Pankhurst CL, Robinson PG. Testing relationships between clinical and non-clinical variables in xerostomia: a structural equation model of oral health-related quality of life. Qual Life Res. 2007;16(2):297–308. Rec #: 37460. Reprint: EXC NRQ. [PubMed: 17033902]
  14. Bangalore M, Matthews S, Suntharalingam M. Recent advances in radiation therapy for head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2007;69(1):1–12. Rec #: 2490. Reprint: EXC NRA. [PubMed: 17085946]
  15. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25(26):4096–4103. Rec #: 37680. Reprint: EXC NRA. [PubMed: 17827459]
  16. Bentzen SM, Wasserman TH. Balancing on a knife’s edge: evidence-based medicine and the marketing of health technology. Int J Radiat Oncol Biol Phys. 2008;72(1):12–14. Rec #: 39250. Reprint: EXC COM. [PubMed: 18722261]
  17. Bhatnagar A, Deutsch M. The Role for intensity modulated radiation therapy (IMRT) in pediatric population. Technol Cancer Res Treat. 2006;(6):591–595. Rec #: 2410. Reprint: EXC N10, NRD. [PubMed: 17121435]
  18. Blanco AI, Chao C. Management of radiation-induced head and neck injury. Cancer Treat Res. 2006;128:23–41. Rec #: 4080. Reprint: EXC NRA. [PubMed: 16335012]
  19. Blanco AI, Chao KS, El Naqa I, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(4):1055–1069. Rec #: 4970. Reprint: EXC NRT, MIXED. [PubMed: 15990009]
  20. Bourhis J, Guigay J, Temam S, et al. Chemo-radiotherapy in head and neck cancer. Ann Oncol. 2006;17(SUPPL 10):x39–x41. Rec #: 17030. Reprint: EXC NRA. [PubMed: 17018748]
  21. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854. Rec #: 30800. Reprint: EXC MA. [PubMed: 16950362]
  22. Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Semin Oncol. 2002;29(6 Suppl 19):63–70. Rec #: 8610. Reprint: EXC NRT, MIXED. [PubMed: 12577248]
  23. Braam PM, Roesink JM, Raaijmakers CP, et al. Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiat Oncol. 2007;2:3. Rec #: 37610. Reprint: EXC 2DR CS. [PMC free article: PMC1779273] [PubMed: 17207274]
  24. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25(8):965–970. Rec #: 1830. Reprint: EXC NRA. [PubMed: 17350945]
  25. Brizel DM. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 1998;8(4):237–246. Rec #: 37470. Reprint: EXC MA. [PubMed: 9873101]
  26. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28. Rec #: 37480. Reprint: EXC MA. [PMC free article: PMC1379652] [PubMed: 16448551]
  27. Bussels B, Maes A, Flamen P, et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol. 2004;73(3):297–306. Rec #: 6110. Reprint: EXC N10. [PubMed: 15588874]
  28. Bussels B, Maes A, Hermans R, et al. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol. 2004;72(2):119–127. Rec #: 6620. Reprint: EXC NRT, MIXED. [PubMed: 15297131]
  29. Butler EB, Teh BS, Grant WH 3rd, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;45(1):21–32. Rec #: 11480. Reprint: EXC N10 IMR. [PubMed: 10477002]
  30. Caglar HB, Allen AM. Intensity-modulated radiotherapy for head and neck cancer. Clin Adv Hematol Oncol. 2007;5(6):425–431. Rec #: 15090. Reprint: EXC NRA. [PubMed: 17679916]
  31. Calais G, Le Floch O. [Concomitant radiotherapy and chemotherapy in the treatment of cancers of the upper respiratory and digestive tracts] Bull Cancer Radiother. 1996;83(4):321–329. Rec #: 37490. Reprint: EXC MA. [PubMed: 9081334]
  32. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):660–665. Rec #: 350. Reprint: EXC CS. [PubMed: 18037580]
  33. Castro JR, Linstadt DE, Bahary J-P, et al. Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys. 1994;29(4):647–655. Rec #: 28540. Reprint: EXC NRD NRT. [PubMed: 8040010]
  34. Cattaneo GM, Ceresoli GL. Optimisation of conformal radiotherapy for lung and nasopharynx cancers: Literature review and clinical experience at HS Raffaele. Phys Med. 2001;17(SUPPL 2):93–102. Rec #: 26310. Reprint: EXC NRA.
  35. Chambers MS, Garden AS, Kies MS, et al. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck. 2004;26(9):796–807. Rec #: 6470. Reprint: EXC NRA. [PubMed: 15350026]
  36. Chambers MS, Garden AS, Rosenthal D, et al. Intensity-modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep. 2005;7(2):131–136. Rec #: 5780. Reprint: EXC NRA. [PubMed: 15717947]
  37. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007;29(1):58–63. Rec #: 2900. Reprint: EXC NRA. [PubMed: 16906511]
  38. Chambers MS, Weber RS, Garden AS. Intensity-modulated radiation therapy and xerostomia. J Calif Dent Assoc. 2006;34(9):743–748. Rec #: 2640. Reprint: EXC NRA. [PubMed: 17022299]
  39. Chan ATC. Head and neck cancer: Treatment of nasopharyngeal cancer. Ann Oncol. 2005;16(SUPPL 2):ii265–ii268. Rec #: 20040. Reprint: EXC NRA. [PubMed: 15958470]
  40. Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2000;54(2):135–142. Rec #: 11090. Reprint: EXC T? [PubMed: 10699476]
  41. Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol. 2002;2(1 Suppl 1):20–25. Rec #: 9670. Reprint: EXC NRA. [PubMed: 11917280]
  42. Chao KS, Bhide S, Chen H, et al. Reduce in variation and improve efficiency of target volume delineation by a computer-assisted system using a deformable image registration approach. Int J Radiat Oncol Biol Phys. 2007;68(5):1512–1521. Rec #: 1190. Reprint: EXC DPN. [PubMed: 17674982]
  43. Chao KS, Low DA, Perez CA, et al. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer. 2000;90(2):92–103. Rec #: 11010. Reprint: EXC N10 IMR. [PubMed: 10814959]
  44. Chao KS, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55(2):312–321. Rec #: 8720. Reprint: EXC NRT, MIXED. [PubMed: 12527043]
  45. Chao KS, Wippold FJ, Ozyigit G, et al. Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys. 2002;53(5):1174–1184. Rec #: 9140. Reprint: EXC DPN NRO. [PubMed: 12128118]
  46. Chen WC, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer. 2006;106(4):820–829. Rec #: 3870. Reprint: EXC N10 NRO. [PubMed: 16421885]
  47. Chen YJ, Kuo JV, Ramsinghani NS, et al. Intensity-modulated radiotherapy for previously irradiated, recurrent head-and-neck cancer. Med Dosim. 2002;27(2):171–176. Rec #: 9320. Reprint: EXC N10 IMR. [PubMed: 12074469]
  48. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23(6):1118–1124. Rec #: 37500. Reprint: EXC 2DR MA. [PubMed: 15657403]
  49. Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol. 2005;28(5):464–471. Rec #: 4460. Reprint: EXC N10 NRT, MIXED. [PubMed: 16199985]
  50. Chua DT, Sham JS, Leung LH, et al. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol. 2005;77(3):290–294. Rec #: 4190. Reprint: EXC NRT, MIXED. [PubMed: 16289398]
  51. Chua DTT, Tian Y, Wei WI. Late oral complications following radiotherapy for head and neck cancers. Expert Rev Anticancer Ther. 2007;7(9):1215–1224. Rec #: 14540. [PubMed: 17892422]
  52. Claus F, Duthoy W, Boterberg T, et al. Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience. Oral Oncol. 2002;38(6):597–604. Rec #: 9050. Reprint: EXC N10 IMR. [PubMed: 12167438]
  53. Cohen SM, Garrett CG, Dupont WD, et al. Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. Ann Otol Rhinol Laryngol. 2006;115(8):581–586. Rec #: 37510. Reprint: EXC NDE NRT. [PubMed: 16944656]
  54. Combs SE, Behnisch W, Kulozik AE, et al. Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer. 2007;7:177. Rec #: 880. Reprint: EXC NRD. [PMC free article: PMC2077337] [PubMed: 17854490]
  55. Corry J, Hornby C, Fisher R, et al. ‘Boomerang’ technique: an improved method for conformal treatment of locally advanced nasopharyngeal cancer. Australas Radiol. 2004;48(2):170–180. Rec #: 6730. Reprint: EXC N10 IMR. [PubMed: 15230751]
  56. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol. 2007;85(1):156–70. Rec #: 1510. Reprint: EXC SR. [PubMed: 17482300]
  57. Cox JD, Fu KK, Pajak TF, et al. Radiation Therapy Oncology Group (RTOG) trials for head and neck cancer. Rays. 2000;25(3):321–323. Rec #: 35850. Reprint: EXC NRA. [PubMed: 11367897]
  58. Das IJ, Cheng CW, Chopra KL, et al. Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst. 2008;100(5):300–307. Rec #: 70. Reprint: EXC DPN. [PubMed: 18314476]
  59. Davies AN, Broadley K, Beighton D. Salivary gland hypofunction in patients with advanced cancer. Oral Oncol. 2002;38(7):680–685. Rec #: 25250. Reprint: EXC T? [PubMed: 12167420]
  60. Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage. 2001;22(4):820–825. Rec #: 26240. Reprint: EXC T? NRD. [PubMed: 11576798]
  61. Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;46(5):1117–1126. Rec #: 11050. Reprint: EXC T?, MIXED. [PubMed: 10725621]
  62. Dawson LA, Myers LL, Bradford CR, et al. Conformal re-irradiation of recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(2):377–385. Rec #: 10320. Reprint: EXC NRT, MIXED. [PubMed: 11380224]
  63. de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2006;64(2):363–373. Rec #: 5150. Reprint: EXC NRT, MIXED. [PubMed: 15925451]
  64. de Castro G Jr, Federico MH. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. Curr Opin Oncol. 2006;18(3):266–270. Rec #: 3620. Reprint: EXC NRA. [PubMed: 16552239]
  65. DeLaney TF. Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center Technol Cancer Res Treat. 2007;6(4 Suppl):61–66. Rec #: 1020. Reprint: EXC NRA. [PubMed: 17668954]
  66. Ding Y, Wu DH, Chen LH. [Value of 18F-fluorodeoxyglucose positron emission tomography in three-dimensional conformal radiotherapy for locally persistent or recurrent nasopharyngeal carcinoma] Di Yi Jun Yi Da Xue Xue Bao. 2005;25(12):1568–1570. Rec #: 4000. Reprint: EXC FLA CS. [PubMed: 16361168]
  67. Dinshaw KA, Agarwal JP, Ghosh-Laskar S, et al. Radical radiotherapy in head and neck squamous cell carcinoma: an analysis of prognostic and therapeutic factors. Clin Oncol (R Coll Radiol) 2006;18(5):383–389. Rec #: 3110. Reprint: EXC NRT, MIXED. [PubMed: 16817329]
  68. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer. 2006;107(11):2525–2534. Rec #: 2510. Reprint: EXC NRA. [PubMed: 17078052]
  69. Douglas JG, Einck J, Austin-Seymour M, et al. Neutron radiotherapy for recurrent pleomorphic adenomas of major salivary glands. Head Neck. 2001;23(12):1037–1042. Rec #: 9860. Reprint: EXC NRT. [PubMed: 11774388]
  70. Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001;92(12):3012–3029. Rec #: 37520. Reprint: EXC 2DR CS. [PubMed: 11753979]
  71. Eisbruch A. Reducing xerostomia by IMRT: what may, and may not, be achieved. J Clin Oncol. 2007;25(31):4863–4864. Rec #: 540. Reprint: EXC COM. [PubMed: 17971579]
  72. Eisbruch A. Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nat Clin Pract Oncol. 2005;2(1):34–39. Rec #: 4300. Reprint: EXC NRA. [PubMed: 16264854]
  73. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(3):695–704. Rec #: 10300. Reprint: EXC T?, MIXED. [PubMed: 11395238]
  74. Eisbruch A, Levendag PC, Feng FY, et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S40–S42. Rec #: 630. Reprint: EXC NRT. [PMC free article: PMC2801073] [PubMed: 17848291]
  75. Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys. 2004;59(1):28–42. Rec #: 7100. Reprint: EXC NRT, MIXED. [PubMed: 15093896]
  76. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5):1425–1439. Rec #: 6070. Reprint: EXC NRO DPN. [PubMed: 15590174]
  77. Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg. 2003;27(7):832–837. Rec #: 7920. Reprint: EXC N10 IMR 3DC. [PubMed: 14509515]
  78. Eisbruch A, Ship JA, Martel MK, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys. 1996;36(2):469–480. Rec #: 12230. Reprint: EXC N10 3DC. [PubMed: 8892473]
  79. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):577–587. Rec #: 11400. Reprint: EXC T?, MIXED. [PubMed: 10524409]
  80. Eisbruch A, Terrell JE, Logemann JA, et al. Letters to the Editor (multiple letters) Head Neck. 2003;25(12):1082–1083. Rec #: 24760. Reprint: EXC LTR. [PubMed: 14648868]
  81. Ernst-Stecken A, Grabenbauer G, Iro H, et al. Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity. Strahlenther Onkol. 2004;80(12):805–810. Rec #: 6030. Reprint: EXC NRT 2DR CS. [PubMed: 15592701]
  82. Feng J, Coppes RP. Can we rescue salivary gland function after irradiation? TheScientificWorld Journal. 2008;8(-):959–962. Rec #: 38890. Reprint: EXC COM. [PubMed: 18836667]
  83. Feng M, Eisbruch A. Future issues in highly conformal radiotherapy for head and neck cancer. J Clin Oncol. 2007;25(8):1009–1013. Rec #: 1820. Reprint: EXC NRA. [PubMed: 17350951]
  84. Feng M, Jabbari S, Lin A, et al. Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiother Oncol. 2005;77(1):32–38. Rec #: 4680. Reprint: EXC NRT, MIXED. [PubMed: 16154219]
  85. Fischer M, Pottgen C, Wechsler S, et al. [Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinomas] HNO. 2007;55(12):950–955. Rec #: 1810. Reprint: EXC FLA, CS. [PubMed: 17356874]
  86. Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94(10):2623–2634. Rec #: 9040. Reprint: EXC NRT, MIXED. [PubMed: 12173330]
  87. Foote RL. Radiotherapy Alone for Early-Stage Squamous Cell Carcinoma of the Larynx and Hypopharynx. Int J Radiat Oncol Biol Phys. 2007;69(2 SUPPL):S31–S36. Rec #: 14900. Reprint: EXC GUI NRA. [PubMed: 17848288]
  88. Fu KK. Combined radiotherapy and chemotherapy for nasopharyngeal carcinoma. Semin Radiat Oncol. 1998;8(4):247–253. Rec #: 37530. Reprint: EXC MA. [PubMed: 9873102]
  89. Fua TF, Corry J, Milner AD, et al. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo-esophageal axis and dysphagia. Int J Radiat Oncol Biol Phys. 2007;67(4):976–981. Rec #: 2070. Reprint: EXC N10. [PubMed: 17234360]
  90. Garden AS, Lewin JS, Chambers MS. How to reduce radiation-related toxicity in patients with cancer of the head and neck. Curr Oncol Rep. 2006;8(2):140–145. Rec #: 3740. Reprint: EXC NRA. [PubMed: 16507224]
  91. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol. 2008;26(2):175–176. Rec #: 250. Reprint: EXC COM. [PubMed: 18182658]
  92. Graff P, Lapeyre M, Desandes E, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67(5):1309–1317. Rec #: 1960. Reprint: EXC NRT, MIXED. [PubMed: 17289292]
  93. Gregoire V, De Neve W, Eisbruch A, et al. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist. 2007;12(5):555–564. Rec #: 1470. Reprint: EXC NRA. [PubMed: 17522243]
  94. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part I. Br J Radiol. 2004;77(914):88–96. Rec #: 7300. Reprint: EXC NRA. [PubMed: 15010378]
  95. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part II. Br J Radiol. 2004;77(915):177–182. Rec #: 37620. Reprint: EXC NRA. [PubMed: 15020357]
  96. Harari PM. Promising new advances in head and neck radiotherapy. Ann Oncol. 2005;16(Suppl 6):vi13–vi19. Rec #: 4980. Reprint: EXC NRA. [PubMed: 15987991]
  97. Herrmann F, Dorr W, Muller R, et al. A prospective study on radiation-induced changes in hearing function. Int J Radiat Oncol Biol Phys. 2006;65(5):1338–1344. Rec #: 3040. Reprint: EXC NRO. [PubMed: 16863923]
  98. Hoppe BS, Nelson CJ, Gomez DR, et al. Unresectable Carcinoma of the Paranasal Sinuses: Outcomes and Toxicities. Int J Radiat Oncol Biol Phys. 2008;72(3):763–769. Rec #: 39040. Reprint: EXC T? [PubMed: 18395361]
  99. Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys. 2007;67(3):691–702. Rec #: 2240. Reprint: EXC T? 2DR 3DC IMR. [PubMed: 17161557]
  100. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: The University of California-San Francisco experience. Cancer. 2008;113(3):497–507. Rec #: 39270. Reprint: EXC NRT, MIXED. [PubMed: 18521908]
  101. Hutcheson KA, Barringer DA, Rosenthal DI, et al. Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2008;134(2):178–183. Rec #: 37810. Reprint: EXC T? [PubMed: 18283161]
  102. Ishii A, Korogi Y, Hirai T, et al. Intraarterial infusion chemotherapy and conformal radiotherapy for cancer of the mouth: prediction of the histological response to therapy with magnetic resonance imaging. Acta Radiol. 2007;48(8):900–906. Rec #: 680. Reprint: EXC T? [PubMed: 17924221]
  103. Jensen K. Measuring side effects after radiotherapy for pharynx cancer. Acta Oncol. 2007;46(8):1051–1063. Rec #: 780. Reprint: EXC NRA. [PubMed: 17882557]
  104. Jensen K, Lambertsen K, Torkov P, et al. Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol. 2007;46(8):1159–1168. Rec #: 890. Reprint: EXC URT. [PubMed: 17851855]
  105. Jereczek-Fossa BA, Garibaldi C, Catalano G, et al. Analysis of mandibular dose distribution in radiotherapy for oropharyngeal cancer: dosimetric and clinical results in 18 patients. Radiother Oncol. 2003;66(1):49–56. Rec #: 8670. Reprint: EXC N10 2DR. [PubMed: 12559520]
  106. Jereczek-Fossa BA, Krengli M, Orecchia R. Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck. 2006;28(8):750–760. Rec #: 3120. Reprint: EXC NRA. [PubMed: 16804876]
  107. Kagei K, Tokuuye K, Sugahara S, et al. [Initial experience of proton beam therapy at the new facility of the University of Tsukuba] Nippon Igaku Hoshasen Gakkai Zasshi. 2004;64(4):225–230. Rec #: 6760. Reprint: EXC FLA CS PBT. [PubMed: 15211886]
  108. Kahn ST, Johnstone PA. Management of xerostomia related to radiotherapy for head and neck cancer. Oncology (Williston Park) 2005;19(14):1827–1832. discussion 1832–1834, 1837–1839. Rec #: 3750. Reprint: EXC NRA. [PubMed: 16506635]
  109. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60(5):1440–1450. Rec #: 6060. Reprint: EXC NRT, MIXED. [PubMed: 15590175]
  110. Kassir RR, Rassekh CH, Kinsella JB, et al. Osteosarcoma of the head and neck: meta-analysis of nonrandomized studies. Laryngoscope. 1997;107(1):56–61. Rec #: 37540. Reprint: EXC MA NRD. [PubMed: 9001266]
  111. Kawamorita R, Yamada K, Nakajima T, et al. Changes in regional body volume and gross tumor volume affect dose distribution during IMRT for head and neck cancer. J JASTRO. 2006;18(4):199–207. Rec #: 18660. Reprint: EXC DPN.
  112. Kearvell R, Kuan R, Preston R, et al. Acute radiation toxicity assessment of a 3-D conformal head and neck radiation treatment technique. Australas Radiol. 2004;48(3):358–363. Rec #: 6500. Reprint: EXC N10 IMR. [PubMed: 15344987]
  113. Kim GE, Lim J, Park HC, et al. A feasibility study using three-dimensional conformal boost technique in locally advanced carcinoma of the nasopharynx. Acta Oncol. 2001;40(5):582–587. Rec #: 10040. Reprint: EXC N10 NRT. [PubMed: 11669329]
  114. King AD, Ahuja AT, Yeung DK, et al. Delayed complications of radiotherapy treatment for nasopharyngeal carcinoma: imaging findings. Clin Radiol. 2007;62(3):195–203. Rec #: 16060. Reprint: EXC NRA. [PubMed: 17293211]
  115. Kinoshita R, Tsuchiya K, Ohmori K, et al. Intensity-Modulated Radiation Therapy (IMRT) for head and neck region. J JASTRO. 2006;18(4):191–197. Rec #: 18650. Reprint: EXC N10 IMR.
  116. Kitamoto Y, Akimoto T, Ishikawa H, et al. Acute toxicity and preliminary clinical outcomes of concurrent radiation therapy and weekly docetaxel and daily cisplatin for head and neck cancer. Jpn J Clin Oncol. 2005;35(11):639–644. Rec #: 4210. Reprint: EXC NRT, MIXED. [PubMed: 16275679]
  117. Kitano M, Nishiguchi I, Aoki Y, et al. [Relation between overall treatment time and local control of early glottic laryngeal cancer: comparison of six versus five times per week] Nippon Igaku Hoshasen Gakkai Zasshi. 2002;62(7):366–369. Rec #: 9100. Reprint: EXC FLA CS. [PubMed: 12136637]
  118. Klem ML, Mechalakos JG, Wolden SL, et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys. 2008;70(4):1100–1107. Rec #: 510. Reprint: EXC N10. [PubMed: 17980501]
  119. Koom WS, Kim TH, Shin KH, et al. SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. Head Neck. 2008;30(2):159–169. Rec #: 950. Reprint: EXC N10. [PubMed: 17764088]
  120. Koukourakis MI, Danielidis V. Preventing radiation induced xerostomia. Cancer Treat Rev. 2005;31(7):546–554. Rec #: 4340. Reprint: EXC NRA. [PubMed: 16257125]
  121. Kristensen CA, Kjaer-Kristoffersen F, Sapru W, et al. Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acta Oncol. 2007;46(2):214–220. Rec #: 1580. Reprint: EXC DPN, N10. [PubMed: 17453372]
  122. Lalami Y, Vereecken P, Dequanter D, et al. Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors. Curr Opin Oncol. 2006;18(3):258–265. Rec #: 3630. Reprint: EXC NRA. [PubMed: 16552238]
  123. Langendijk JA. New developments in radiotherapy of head and neck cancer: Higher precision with less patient discomfort? Radiother Oncol. 2007;85(1):1–6. Rec #: 16310. Reprint: EXC NRA. [PubMed: 17854932]
  124. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22(22):4604–4612. Rec #: 37550. Reprint: EXC MA. [PubMed: 15542811]
  125. Langer CJ, Duffy K, Horwitz EM, et al. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naive locally advanced upper aerodigestive malignancy. Cancer Invest. 2006;24(2):164–173. Rec #: 3690. Reprint: EXC NRT, MIXED. [PubMed: 16537186]
  126. Laskar SG, Agarwal JP, Srinivas C, et al. Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2006;6(3):405–417. Rec #: 3760. Reprint: EXC NRA. [PubMed: 16503857]
  127. Lauve A, Morris M, Schmidt-Ullrich R, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. Int J Radiat Oncol Biol Phys. 2004;60(2):374–387. Rec #: 6420. Reprint: EXC N10 IMR. [PubMed: 15380569]
  128. Le QT. Nasopharyngeal and oropharyngeal carcinomas: target delineation, therapy delivery and stereotactic boost procedures with intensity-modulated/image-guided radiation therapy. Front Radiat Ther Oncol. 2007;40:208–231. Rec #: 1270. Reprint: EXC NRA. [PubMed: 17641511]
  129. Lee AW, Yau TK, Wong DH, et al. Treatment of stage IV(A–B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys. 2005;63(5):1331–1338. Rec #: 4580. Reprint: EXC NRT, MIXED. [PubMed: 16169677]
  130. Lee N, Puri DR, Blanco AI, et al. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck. 2007;29(4):387–400. Rec #: 4030. Reprint: EXC NRA. [PubMed: 16358297]
  131. Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57(1):49–60. Rec #: 8040. Reprint: EXC NRT, MIXED. [PubMed: 12909215]
  132. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53(1):12–22. Rec #: 9540. Reprint: EXC NRT, MIXED. [PubMed: 12007936]
  133. Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol. 2008;35(3):236–250. Rec #: 37760. Reprint: EXC NRA. [PMC free article: PMC2494523] [PubMed: 18544439]
  134. Lee SW, Back GM, Yi BY, et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65(1):152–160. Rec #: 3830. Reprint: EXC N10. [PubMed: 16472934]
  135. Levendag P, Nijdam W, Noever I, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys. 2004;59(3):713–724. Rec #: 6820. Reprint: EXC NRT, MIXED. [PubMed: 15183475]
  136. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol. 2007;85(1):64–73. Rec #: 1000. Reprint: EXC T? [PubMed: 17714815]
  137. Li Y, Taylor JM, Ten Haken RK, et al. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67(3):660–669. Rec #: 2360. Reprint: EXC T? NRO. [PMC free article: PMC2001308] [PubMed: 17141973]
  138. Liauw SL, Mancuso AA, Morris CG, et al. Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: incomplete radiographic response does not necessarily indicate failure. Int J Radiat Oncol Biol Phys. 2006;66(4):1017–1021. Rec #: 2320. Reprint: EXC N10. [PubMed: 17145530]
  139. Licitra L. Chemoradiation therapy in locally advanced nasopharyngeal cancer: Which kind of cooperation? Ann Oncol. 2003;14(4):508–509. Rec #: 23550. Reprint: EXC EDT. [PubMed: 12649094]
  140. Licitra L, Locati LD, Bossi P. Head and neck cancer. Ann Oncol. 2004;15(SUPPL 4):iv267–iv273. Rec #: 21450. Reprint: EXC NRA. [PubMed: 15477319]
  141. Lin OS, Mannava S, Hwang KL, et al. Reasons for current practices in managing Barrett’s esophagus. Dis Esophagus. 2002;15(1):39–45. Rec #: 9440. Reprint: EXC NRD. [PubMed: 12060041]
  142. Lin R, Slater JD, Yonemoto LT, et al. Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy--dose-volume histogram analysis. Radiology. 1999;213(2):489–494. Rec #: 11340. Reprint: EXC N10 PBT. [PubMed: 10551231]
  143. Liu WS, Kuo HC, Lin JC, et al. Assessment of salivary function change in nasopharyngeal carcinoma treated by parotid-sparing radiotherapy. Cancer J. 2006;12(6):494–500. Rec #: 2170. Reprint: EXC NRT, MIXED. [PubMed: 17207319]
  144. Liu WS, Lee SP, Lee JK, et al. Factors influencing the parotid function in nasopharyngeal carcinoma treated with parotid-sparing radiotherapy. Jpn J Clin Oncol. 2006;36(10):626–631. Rec #: 2680. Reprint: EXC T?, MIXED. [PubMed: 17008345]
  145. Liu WS, Su MC, Wu MF, et al. Nasopharyngeal carcinoma treated with precision-oriented radiation therapy techniques including intensity-modulated radiotherapy: preliminary results. Kaohsiung J Med Sci. 2004;20(2):49–55. Rec #: 6310. Reprint: EXC N10 IMR. [PubMed: 15481551]
  146. Logemann JA, Pauloski BR, Rademaker AW, et al. Swallowing disorders in the first year after radiation and chemoradiation. Head Neck. 2008;30(2):148–158. Rec #: 13610. Reprint: EXC URT. [PMC free article: PMC2903205] [PubMed: 17786992]
  147. Lu H, Yao M. The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev. 2008;34(1):27–36. Rec #: 710. Reprint: EXC NRA. [PubMed: 17910906]
  148. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. J Clin Oncol. 2008;26(15):2590–2591. Rec #: 39120. Reprint: EXC LTR. [PubMed: 18443349]
  149. MacDonald SM, DeLaney TF, Loeffler JS. Proton beam radiation therapy. Cancer Invest. 2006;24(2):199–208. Rec #: 18480. Reprint: EXC NRA PBT. [PubMed: 16537190]
  150. Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol. 2002;63(2):203–211. Rec #: 9380. Reprint: EXC NRT, MIXED. [PubMed: 12063010]
  151. McLean JN, Nunley SR, Klass C, et al. Combined modality therapy of esthesioneuroblastoma. Otolaryngol Head Neck Surg. 2007;136(6):998–1002. Rec #: 1440. Reprint: EXC N10. [PubMed: 17547995]
  152. McMillan AS. Oral health and quality of life following radiotherapy for nasopharyngeal carcinoma. J HK Coll Radiol. 2003;6(2):75–77. Rec #: 24650. Reprint: EXC 2DR CS.
  153. Mendenhall WM. In Reply to Drs. Studer and Glanzmann. Int J Radiat Oncol Biol Phys. 2008;72(4):1272. Rec #: 38810. Reprint: EXC LTR.
  154. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol. 2006;24(17):2618–2623. Rec #: 3180. Reprint: EXC NRA. [PubMed: 16763274]
  155. Mendenhall WM, Mancuso AA, Hinerman RW, et al. Multidisciplinary management of laryngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(2 SUPPL):S12–S14. Rec #: 14880. Reprint: EXC NRA. [PubMed: 17848278]
  156. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol. 2006;29(3):290–297. Rec #: 3190. Reprint: EXC NRT, MIXED. [PubMed: 16755183]
  157. Mendenhall WM, Morris CG, Hinerman RW, et al. Definitive radiotherapy for nasopharyngeal carcinoma. Am J Clin Oncol. 2006;29(6):622–627. Rec #: 2280. Reprint: EXC T? URT IMR. [PubMed: 17149001]
  158. Meyer J, Hummel SM, Cho PS, et al. Automatic selection of non-coplanar beam directions for three-dimensional conformal radiotherapy. Br J Radiol. 2005;78(928):316–327. Rec #: 20700. Reprint: EXC PHY. [PubMed: 15774592]
  159. Meyer JL, Eisbruch A, Le QT. A discussion of the clinical use of advanced technologies in head and neck radiotherapy. Front Radiat Ther Oncol. 2007;40:232–238. Rec #: 1260. Reprint: EXC COM. [PubMed: 17641512]
  160. Milano MT, Haraf DJ, Stenson KM, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004;10(15):4922–4932. Rec #: 6600. Reprint: EXC 2DR CS. [PubMed: 15297392]
  161. Milano MT, Vokes EE, Kao J, et al. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006;28(5):1141–1151. Rec #: 3520. Reprint: EXC NRT, MIXED. [PubMed: 16596230]
  162. Munter MW, Hoffner S, Hof H, et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys. 2007;67(3):651–659. Rec #: 2230. Reprint: EXC NRO. [PubMed: 17175118]
  163. Munter MW, Karger CP, Hoffner SG, et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys. 2004;58(1):175–184. Rec #: 7540. Reprint: EXC N10 IMR. [PubMed: 14697436]
  164. Murata Y, Zhang L, Ishida R, et al. Maintained salivary function after brachytherapy in patients with head and neck carcinomas--evaluation using quantitative salivary gland scintigraphy. Acta Oncol. 2002;41(7–8):684–688. Rec #: 7640. Reprint: EXC NRT BRA. [PubMed: 14651214]
  165. Murayama S, Fuji H, Yamashita H, et al. [Initial clinical experience of proton therapy at Shizuoka Cancer Center] Nippon Igaku Hoshasen Gakkai Zasshi. 2005;65(4):424–431. Rec #: 4090. Reprint: EXC FLA CS PBT. [PubMed: 16334397]
  166. Murdoch-Kinch C-A, Kim HM, Vineberg KA, et al. Dose-Effect Relationships for the Submandibular Salivary Glands and Implications for Their Sparing by Intensity Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(2):373–382. Rec #: 39100. Reprint: EXC T? [PMC free article: PMC3734803] [PubMed: 18337023]
  167. Nangia S, Chufal KS, Arivazhagan V, et al. Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation. Clin Oncol (R Coll Radiol) 2006;18(6):485–492. Rec #: 2890. Reprint: EXC N10. [PubMed: 16909973]
  168. Ng MK, Porceddu SV, Milner AD, et al. Parotid-sparing radiotherapy: does it really reduce xerostomia? Clin Oncol (R Coll Radiol) 2005;17(8):610–617. Rec #: 3980. Reprint: EXC NRT, MIXED. [PubMed: 16372486]
  169. Ng WT, Chan SH, Lee AWM, et al. Parapharyngeal extension of nasopharyngeal carcinoma: still a significant factor in era of modern radiotherapy? Int J Radiat Oncol Biol Phys. 2008;72(4):1082–1089. Rec #: 38880. Reprint: EXC NRT, MIXED. [PubMed: 18410997]
  170. Nishioka T, Shirato H, Kagei K, et al. Three-dimensional small-volume irradiation for residual or recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000;48(2):495–500. Rec #: 10730. Reprint: EXC N10 3DC. [PubMed: 10974467]
  171. Nutting C. Intensity-modulated radiotherapy (IMRT): The most important advance in radiotherapy since the linear accelerator? Br J Radiol. 2003;76(910):673. Rec #: 23480. Reprint: EXC EDT. [PubMed: 14512325]
  172. O’Meara WP, Lee N. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2005;17(3):225–230. Rec #: 5390. Reprint: EXC NRA. [PubMed: 15818165]
  173. Ohizumi Y, Tamai Y, Imamiya S, et al. Prediction of tumor control by tumor regression at 40 Gy/4 weeks of external beam irradiation for oropharyngeal carcinoma. Radiat Med Med Imaging Radiat Oncol. 2004;22(5):324–331. Rec #: 21610. Reprint: EXC 2DR CS. [PubMed: 15553013]
  174. Ozyigit G, Chao KS. Clinical experience of head-and-neck cancer IMRT with serial tomotherapy. Med Dosim. 2002;27(2):91–98. Rec #: 9310. Reprint: EXC NRO. [PubMed: 12074473]
  175. Pan JJ, Wu JX, Zhang XC, et al. High dose rate conformal brachytherapy for nasopharyngeal carcinoma: A preliminary study. Curr Oncol. 1998;5(1):28–32. Rec #: 27810. Reprint: EXC NRT.
  176. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58(3):663–673. Rec #: 7380. Reprint: EXC N10 IMR. [PubMed: 14967418]
  177. Paulino AC, Koshy M. Patterns of failure after IMRT for head-and-neck cancer: let's not count the chickens before the eggs hatch. Int J Radiat Oncol Biol Phys. 2003;56(5):1508. author reply 1508. Rec #: 8110. Reprint: EXC COM. [PubMed: 12873698]
  178. Paulsen F, Belka C, Alber M, et al. Intensity-Modulated radiotherapy: INTENSITATSMODULIERTE STRAHLENTHERAPIE. Onkologe. 2003;9(3):315–325. Rec #: 24050. Reprint: EXC FLA D?
  179. Perez CA, Purdy JA, Harms W, et al. Three-dimensional treatment planning and conformal radiation therapy: preliminary evaluation. Radiother Oncol. 1995;36(1):32–43. Rec #: 12490. Reprint: EXC NRO. [PubMed: 8525023]
  180. Pignon JP, Baujat B, Bourhis J. [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?] Cancer Radiother. 2005;9(1):31–36. Rec #: 37560. Reprint: EXC FLA MA. [PubMed: 15804617]
  181. Pigott K, Dische S, Saunders MI. Where exactly does failure occur after radiation in head and neck cancer? Radiother Oncol. 1995;37(1):17–19. Rec #: 12470. Reprint: EXC NRT URT. [PubMed: 8539452]
  182. Ploquin N, Lau H, Dunscombe P. Intensity modulated and three-dimensional conformal radiation therapy plans for oropharyngeal cancer: A comparison of their sensitivity to set-up errors and uncertainties. Curr Oncol. 2006;13(2):61–66. Rec #: 18160. Reprint: EXC DPC IMR 3DC. [PMC free article: PMC1891170] [PubMed: 17576443]
  183. Popovtzer A, Eisbruch A. Advances in radiation therapy of head and neck cancer. Expert Rev Anticancer Ther. 2008;8(4):633–644. Rec #: 28850. Reprint: EXC NRA. [PubMed: 18402530]
  184. Posner MR. IMRT bests standard RT in long-term QOL in head and neck cancer patients. Oncol Rep. 2005 SPRING;:69–70. Rec #: 20730. Reprint: EXC CR.
  185. Posner MR. Early postop chemo/chemoradiation feasible in high-risk head and neck cancer. Oncol Rep. 2005 SPRING;:77–78. Rec #: 20750. Reprint: EXC CR.
  186. Puri DR, Chou W, Lee N. Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results. Am J Clin Oncol. 2005;28(4):415–423. Rec #: 4820. Reprint: EXC NRA. [PubMed: 16062086]
  187. Qadeer MA, Lopez R, Wood BG, et al. Does acid suppressive therapy reduce the risk of laryngeal cancer recurrence? Laryngoscope. 2005;115(10 I):1877–1881. Rec #: 19360. Reprint: EXC NRQ. [PubMed: 16222214]
  188. Rabbani A, Amdur RJ, Mancuso AA, et al. Definitive radiotherapy for T1–T2 squamous cell carcinoma of pyriform sinus. Int J Radiat Oncol Biol Phys. 2008;72(2):351–355. Rec #: 39080. Reprint: EXC 2DR T? [PubMed: 18395359]
  189. Redda MGR, Succo G, Guarneri A, et al. Radiotherapy after surgery for advanced adenoid cystic carcinoma of paranasal sinus. Lancet Oncol. 2005;6(12):994–996. Rec #: 19060. Reprint: EXC CR. [PubMed: 16321768]
  190. Robinson MH. Radiotherapy: technical aspects. Medicine (GBR) 2008;36(1):9–14. Rec #: 13900. Reprint: EXC NRA.
  191. Ronis DL, Duffy SA, Fowler KE, et al. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134(3):241–248. Rec #: 37800. Reprint: EXC T? [PubMed: 18347247]
  192. Rudat V, Munter M, Rades D, et al. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol. 2008;89(1):71–80. Rec #: 38910. Reprint: EXC NRO. [PubMed: 18707782]
  193. Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol. 2005;74(3):251–258. Rec #: 5600. Reprint: EXC N10 IMR. [PubMed: 15763305]
  194. Salama JK, Haraf DJ, Stenson K, et al. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005;11(2):140–146. Rec #: 5060. Reprint: EXC NRT, MIXED. [PubMed: 15969989]
  195. Salama JK, Stenson KM, List MA, et al. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134(10):1060–1065. Rec #: 38300. Reprint: EXC T? [PubMed: 18936351]
  196. Sanderson RJ, Ironside JAD. Squamous cell carcinomas of the head and neck. Br Med J. 2002;325(7368):822–827. Rec #: 25080. Reprint: EXC NRA. [PMC free article: PMC1124330] [PubMed: 12376446]
  197. Schulz-Ertner D, Nikoghosyan A, Jakel O, et al. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Radiat Oncol Biol Phys. 2003;56(2):391–398. Rec #: 8320. Reprint: EXC NRT, MIXED. [PubMed: 12738314]
  198. Scrimger RA, Stavrev P, Parliament MB, et al. Phenomenologic model describing flow reduction for parotid gland irradiation with intensity-modulated radiotherapy: evidence of significant recovery effect. Int J Radiat Oncol Biol Phys. 2004;60(1):178–185. Rec #: 6520. Reprint: EXC N10 IMR. [PubMed: 15337554]
  199. Selek U, Garden AS, Morrison WH, et al. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2004;59(3):743–751. Rec #: 33430. Reprint: EXC URT. [PubMed: 15183477]
  200. Shin SS, Ahn YC, Lim DH, et al. High dose 3-dimensional re-irradiation for locally recurrent nasopharyngeal cancer. Yonsei Med J. 2004;45(1):100–106. Rec #: 7310. Reprint: EXC N10 3DC. [PubMed: 15004875]
  201. Slater JD. Clinical applications of proton radiation treatment at Loma Linda University: Review of a fifteen-year experience. Technol Cancer Res Treat. 2006;5(2):81–89. Rec #: 17950. Reprint: EXC NRA PBT. [PubMed: 16551128]
  202. Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005;62(2):494–500. Rec #: 5270. Reprint: EXC NRT, MIXED. [PubMed: 15890592]
  203. Smith A, Goitein M, Flanz J, et al. The Northeast Proton Therapy center at Massachusetts General Hospital. J Brachytherapy Int. 1997;13(1):137–139. Rec #: 27930. Reprint: EXC NRA.
  204. Smith AR. Against the proposition. Med Phys. 1999;26(7):1187. Rec #: 27550. Reprint: EXC NRD NRQ.
  205. Stokman MA, Spijkervet FK, Boezen HM, et al. Preventive intervention possibilities in radiotherapy-and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res. 2006;85(8):690–700. Rec #: 37570. Reprint: EXC NRQ MA. [PubMed: 16861284]
  206. Studer G, Luetolf UM, Glanzmann C. Locoregional failure analysis in head-and-neck cancer patients treated with IMRT. Strahlenther Onkol. 2007;183(8):417–423. discussion 424–425. Rec #: 1140. Reprint: EXC precursor study to rec#38640. [PubMed: 17680220]
  207. Studer GM, Glanzmann C. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer: in regard to Schoenfeld et al. (Int J Radiat Oncol Biol Phys 2008;71:377–385) Int J Radiat Oncol Biol Phys. 2008;72(4):1271–1272. author reply 1272. Rec #: 38270. Reprint: EXC COM. [PubMed: 18954722]
  208. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997;37(2):259–267. Rec #: 37580. Reprint: EXC MA. [PubMed: 9069295]
  209. Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2000;48(3):711–722. Rec #: 10700. Reprint: EXC NRT, MIXED. [PubMed: 11020568]
  210. Suzuki G, Hayabuchi N, Kojima K, et al. Treatment outcome of nasopharynx cancer: Dose presence of MR findings of extracapsular spread in cervical node metastasis influence distant metastasis? J JASTRO. 2004;16(2):95–100. Rec #: 22050. Reprint: EXC T?
  211. Tang YQ, Luo W, He ZC, et al. [Three-dimensional conformal radiotherapy for primary nasopharyngeal carcinoma and analysis of locoregional recurrence] Ai Zheng. 2006;25(3):330–334. Rec #: 3700. Reprint: EXC FLA CS. [PubMed: 16536988]
  212. Taylor A, Powell ME. Intensity-modulated radiotherapy - what is it? Cancer Imaging. 2004;4(2):68–73. Rec #: 37630. Reprint: EXC NRA. [PMC free article: PMC1434586] [PubMed: 18250011]
  213. Teguh DN, Levendag PC, Noever I, et al. Treatment Techniques and Site Considerations Regarding Dysphagia-Related Quality of Life in Cancer of the Oropharynx and Nasopharynx. Int J Radiat Oncol Biol Phys. 2008;72(4):1119–1127. Rec #: 38860. Reprint: EXC NRT, MIXED. [PubMed: 18472364]
  214. Teo PM, Ma BB, Chan AT. Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods. Radiother Oncol. 2004;73(2):163–172. Rec #: 6220. Reprint: EXC NRA. [PubMed: 15542163]
  215. Terezakis SA, Bohle GC 3rd, Lee NY. Fistula formation after postoperative radiation treatment for paranasal sinus cancer. Am J Clin Oncol. 2008;31(2):199–204. Rec #: 10. Reprint: EXC NRA. [PubMed: 18391607]
  216. Terhaard CHJ. Postoperative and Primary Radiotherapy for Salivary Gland Carcinomas: Indications, Techniques, and Results. Int J Radiat Oncol Biol Phys. 2007;69(2 SUPPL):S52–S55. Rec #: 14890. Reprint: EXC NRA. [PubMed: 17848295]
  217. Thariat J, Ahamad A, El-Naggar AK, et al. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: A case-control study. Cancer. 2008;112(12):2698–2709. Rec #: 39220. Reprint: EXC T? [PubMed: 18429002]
  218. Thorstad WL, Haughey B, Chao KS. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. Semin Oncol. 2003;30(6 Suppl 18):96–100. Rec #: 7460. Reprint: EXC N10 IMR. [PubMed: 14727249]
  219. Tokuuye K, Akine Y, Kagei K, et al. Proton therapy for head and neck malignancies at Tsukuba. Strahlenther Onkol. 2004;180(2 ):96–101. Rec #: 7390. Reprint: EXC NRT, MIXED. [PubMed: 14762662]
  220. Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25(32):5121–5127. Rec #: 37690. Reprint: EXC NRA. [PubMed: 17991931]
  221. Tsao AS, Garden AS, Kies MS, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006;24(25):4163–4169. Rec #: 30810. Reprint: EXC 2DR CS. [PubMed: 16943532]
  222. Uchida D, Shirato H, Onimaru R, et al. Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J. 2005;11(2):152–156. Rec #: 5050. Reprint: EXC NRT, MIXED. [PubMed: 15969991]
  223. Veldeman L, Madani I, Hulstaert F, et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008;9(4):367–375. Rec #: 13370. Reprint: EXC MA. [PubMed: 18374290]
  224. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2008;70(3):678–684. Rec #: 110. Reprint: EXC Q? [PubMed: 18262086]
  225. Vissink A, Burlage FR, Spijkervet FK, et al. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):213–225. Rec #: 37640. Reprint: EXC NRA. [PubMed: 12799324]
  226. Vissink A, Jansma J, Spijkervet FK, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):199–212. Rec #: 37650. Reprint: EXC NRA. [PubMed: 12799323]
  227. Wadsley JC, Bentzen SM. Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;60(5):1405–1409. Rec #: 37590. Reprint: EXC MA. [PubMed: 15590171]
  228. Waldron J, Tin MM, Keller A, et al. Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiother Oncol. 2003;68(2):153–161. Rec #: 7950. Reprint: EXC 2DR CS. [PubMed: 12972310]
  229. Warde P. Radiotherapy: practical applications and clinical aspects. Medicine (GBR) 2008;36(1):15–18. Rec #: 13910. Reprint: EXC NRA.
  230. Weber DC, Chan AW, Lessell S, et al. Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. Radiother Oncol. 2006;81(3):243–249. Rec #: 2620. Reprint: EXC NRT, MIXED. [PubMed: 17050017]
  231. Wijers OB, Levendag PC, Luyten GPM, et al. Radiation-induced bilateral optic neuropathy in cancer of the nasopharynx: Case failure analysis and a review of the literature. Strahlenther Onkol. 1999;175(1):21–27. Rec #: 27650. Reprint: EXC CR NRA. [PubMed: 9951514]
  232. Willins J, Kachnic L. Clinically relevant standards for intensity-modulated radiation therapy dose prescription. J Natl Cancer Inst. 2008;100(5):288–290. Rec #: 37670. Reprint: EXC COM. [PubMed: 18314470]
  233. Withers HR, Peters LJ. Comment on Editorial “Magical Protons” by Dr. Michael Goitein (Int J Radiat Oncol Biol Phys 2008;70:654–656) and in Reply to Dr. Fowler. Int J Radiat Oncol Biol Phys. 2008;72(4):1271. Rec #: 38830. Reprint: EXC COM. [PubMed: 18954723]
  234. Wolden SL, Zelefsky MJ, Hunt MA, et al. Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2001;49(5):1229–1234. Rec #: 10420. Reprint: EXC NRT, MIXED. [PubMed: 11286827]
  235. Wu DH, Chen LH. [Therapeutic effects of three-dimensional conformal radiation therapy for locally recurrent nasopharyngeal carcinoma] Di Yi Jun Yi Da Xue Xue Bao. 2002;22(11):1028–1029. Rec #: 8860. Reprint: EXC FLA 3DC. [PubMed: 12433640]
  236. Wu Q, Mohan R, Morris M, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. Int J Radiat Oncol Biol Phys. 2003;56(2):573–585. Rec #: 8310. Reprint: EXC N10 IMR. [PubMed: 12738335]
  237. Wu VWC, Kwong DWL, Sham JST, et al. Auto-optimisation for three-dimensional conformal radiotherapy of nasopharyngeal carcinoma. Radiography. 2003;9(3):201–210. Rec #: 23240. Reprint: EXC DPN.
  238. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys. 2004;60(5):1410–1418. Rec #: 6090. Reprint: EXC NRO RAD. [PubMed: 15590172]
  239. Yau TK, Lee AW, Wong DH, et al. Treatment of Stage IV(A–B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys. 2006;66(4):1004–1010. Rec #: 2330. Reprint: EXC O? [PubMed: 17145529]
  240. Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65(1):161–168. Rec #: 3680. Reprint: EXC NRT, MIXED. [PubMed: 16542792]
  241. Zackrisson B, Mercke C, Strander H, et al. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 2003;42(5–6):443–461. Rec #: 37600. Reprint: EXC SR. [PubMed: 14596506]
  242. Zhang X-C, Shi M, Xiao F, et al. Clinical study of 73 local-advanced nasopharyngeal carcinoma patients treated with chemoradiotherapy. Chin J Cancer Prev Treat. 2007;14(22):1710–1713. Rec #: 14410. Reprint: INC QEX 2DR IMR.
  243. Zhang Y, Pan J-J, Zheng Z, et al. Analysis of recurrent cases after IMRT in nasopharyngeal carcinoma. Chin J Cancer Prev Treat. 2007;14(13):1011–1013. Rec #: 15060. Reprint: EXC FLA CS IMR.
  244. Zhao C, Han F, Lu LX, et al. [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma] Ai Zheng. 2004;23(11 Suppl):1532–1537. Rec #: 6150. Reprint: EXC FLA CS IMR. [PubMed: 15566674]
  245. Zheng XK, Chen LH, Chen YQ, et al. Three-dimensional conformal radiotherapy versus intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;60(1):165–170. Rec #: 6530. Reprint: EXC NRT, MIXED. [PubMed: 15337552]
  246. Zheng X-K, Ma J, Xia Y-F, et al. Three-dimensional conformal radiation therapy for locally recurrent nasopharyngeal carcinoma. Chin J Cancer Res. 2001;13(3):221–225. Rec #: 26180. Reprint: EXC NRT, MIXED.

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...